US EditionPublished • loading... • Updated
CeleCor Nearing Regulatory Approval of Heart Attack Drug
Summary by San Diego Business Journal
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
CeleCor Nearing Regulatory Approval of Heart Attack Drug
DEL MAR – Pharmaceutical developer CeleCor Therapeutics is poised to submit its investigational heart attack drug zalunfiban to federal regulators for approval in early 2026 following positive results from the drug’s Phase 3 clinical study. Zalunfiban is a rapid pre-hospital treatment for patients suffering from an ST-elevation myocardial infarction (STEMI), one of the most severe […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
